Spago Nanomedical AB has shared preliminary findings from its phase IIa clinical study, SPAGOPIX-02, indicating a promising safety profile for its drug candidate, SN132D, in patients with endometriosis. The study aims to evaluate the safety and MRI-enhancing properties of SN132D in individuals suspected of having endometriosis. Initial analysis by the study’s Data Monitoring Committee revealed that SN132D was well tolerated by patients with endometriosis. However, further assessment is required before determining the drug’s efficacy. The committee also stated that the current number of recruited patients (n=8) provides a sufficient basis for assessment, leading to a temporary pause in recruitment.
SN132D is a contrast agent that was previously evaluated in the phase I clinical study, SPAGOPIX-01, involving patients with confirmed breast cancer. Preliminary results from this study demonstrated the drug’s ability to provide clear contrast in MRI images of solid tumors in the breast, pancreas, and liver, while also being well tolerated. A final report for the study is currently being prepared.
Mats Hansen, the CEO of Spago Nanomedical, expressed satisfaction with the positive safety profile exhibited by SN132D, emphasizing the significance of safety in all development programs related to the company’s platform material. Hansen looks forward to the full analysis of the study’s results, which will play a crucial role in determining the drug’s further development.
The ongoing evaluation of SN132D’s MRI contrast enhancing properties, particularly in lesions indicative of deep endometriosis, will provide valuable insights into the drug’s potential efficacy. While the results look promising in terms of safety, further analysis is necessary to draw definitive conclusions. Spago Nanomedical remains committed to advancing the study and refining the drug’s properties to maximize its potential as a treatment option for endometriosis patients.
